SHIELD · Strategies for Healing Implant-associated infections and Enhancing Longevity in Devices
Horizon Europe — Marie Skłodowska-Curie Actions
- Duration
- 2025-09-01 → 2029-08-31
- EU contribution
- €4,725,090
- Participants
- 27
- Scheme
- HORIZON-TMA-MSCA-DN
Lines connect the coordinator with its partners.
Project objective
Medical implants have revolutionised healthcare by improving quality of life through replacing missing structures, restoring function, and promoting tissue regeneration. However, implant-associated infections (IAIs) undermine these benefits, particularly in orthopaedics, otology, and odontology, leading to chronic issues and substantial healthcare costs. IAIs, exacerbated by biofilm formation and antimicrobial resistance, pose a significant public health challenge. The SHIELD doctoral network aims to advance our understanding of IAIs, from their multifactorial pathogenesis to the development of new antibacterial biomaterials, bridging the gap between basic research and practical applications.SHIELD is structured around three scientific pillars to advance IAI control strategies in orthopaedics, otology, and odontology: regenerative medicine, biomaterial science, and translational research models. These pillars drive research on therapeutic strategies, innovative biomaterials, and experimental proof-of-concept models. The network focuses on clinical studies, antimicrobial strategies for implants, and preclinical models to study IAI mechanisms.Our goal is to train 16 young researchers through an interdisciplinary and translational approach, combining basic research with preclinical and clinical testing. In collaboration with 27 partners from 11 countries, SHIELD brings together expertise from multiple disciplines to bridge the gap between research and real-world applications. By developing new antimicrobial solutions for implants and conducting bench-to-bedside research, SHIELD aims to improve infection management protocols and patient care, significantly advancing the field of infection control in medical devices.
Original text from CORDIS.
Participants
- GOETEBORGS UNIVERSITET · GoeteborgCoordinatorSweden
- ANTHOGYR SAS · SallanchesFrance
- AO FORSCHUNGSINSTITUT DAVOS · Davos PlatzSwitzerland
- ASHLAND SPECIALTIES IRELAND LIMITED · MullingarIreland
- Amicoat AS · TromsøNorway
- CORTICALIS AS · OsloNorway
- FUNDACION PUBLICA MIGUEL SERVET · PamplonaSpain
- HOSPICES CIVILS DE LYON · LyonFrance
- Heraeus Medical GmbH · WehrheimGermany
- KLINIKUM DER UNIVERSITAET REGENSBURG · RegensburgGermany
- Montana State University Bozeman · BozemanUnited States
- Oticon Medical AB · AskimSweden
- PHAXIAM THERAPEUTICS · LyonFrance
- ROYAL COLLEGE OF SURGEONS IN IRELAND · DUBLIN 2Ireland
- TECHNISCHE UNIVERSITAET DRESDEN · DresdenGermany
- THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE · CAMBRIDGEUnited Kingdom
- THE UNIVERSITY OF BIRMINGHAM · BirminghamUnited Kingdom
- UNIVERSIDAD PUBLICA DE NAVARRA · PamplonaSpain
- UNIVERSITA DEGLI STUDI DI TORINO · TorinoItaly
- UNIVERSITAET REGENSBURG · RegensburgGermany
- UNIVERSITAT AUTONOMA DE BARCELONA · Cerdanyola Del VallesSpain
- UNIVERSITE LYON 1 CLAUDE BERNARD · Villeurbanne CedexFrance
- UNIVERSITETET I OSLO · OsloNorway
- UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK · CorkIreland
- UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN · DublinIreland
- UNIVERSITY OF SOUTHAMPTON · SOUTHAMPTONUnited Kingdom
- YELLOW RESEARCH · AmsterdamNetherlands
Links
Data: CORDIS, © European Union